Tilogotamab (GEN-1029) is an enhanced hexameric mixture of two agonistic antibodies that bind to distinct epitopes on death receptor type 5 (DR5), specifically activating it. This compound is utilized in the research of multiple myeloma (MM) [1].

Tilogotamab at a concentration of 20 μg/mL for 24 hours exhibits potent cytotoxicity against primary MM cells [1]. Tilogotamab is a mixture of two non-competitive DR5-specific monoclonal immunoglobulin G1 (IgG1) antibodies, each featuring an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, leading to antibody hexamerization and subsequent FcγR-independent clustering of DR5 molecules [1].